{"disease":{"id":"usher-syndrome-type-2","name":"usher syndrome type 2"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT04820244","title":"Characterizing Rate of Progression in USHer Syndrome (CRUSH) Study","phase":"","overall_status":"UNKNOWN","enrollment_count":36,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT05085964","title":"An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"Laboratoires Thea","has_results":true},{"nct_id":"NCT03780257","title":"Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"ProQR Therapeutics","has_results":false},{"nct_id":"NCT05158296","title":"Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Laboratoires Thea","has_results":true},{"nct_id":"NCT05176717","title":"Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Laboratoires Thea","has_results":true}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}